Overactive Bladder
Conditions
Brief summary
The purpose of this study is to determine whether Succinate of Solifenacin reduces the OverActive Bladder syndrome occurring during prostate irradiation.
Detailed description
A multicenter Phase III, randomized, double-blinded, parallel group placebo-controlled study. 2 groups: * Control arm = pts. with placebo * Experimental arm = pts. with Solifenacin succinate 5 mg - Vesicare® All patients with an OAB sub-score using the USP scale greater to 5 during prostate cancer radiotherapy will be included, receiving either a placebo or Solifenacin succinate (5mg) for duration of 3 months. The randomization will be stratified on the radiotherapy dose (1 to 40 Gy or 40 to 70/80 Gy). Screening: For all patients, OAB items of the USP scale will be completed before each standard weekly assessment during prostate radiotherapy. Patients who reach an OAB sub-score greater to 5 will be addressed to an urologist in order to confirm absence of Qmax \< 10ml/sec at initial assessment, or post-void residual urine \> 100 milliliter (ml). Inclusion & treatment: A week at most after pre-screening, patients will be randomized to receive either Vesicare®-5mg or a placebo. In both study arms, the treatment should be continued for 3 months. Follow-up: The radiation oncologist will perform patients' follow-up for the study at the treatment initiation, 6 weeks and 3 months after start of the treatment (Vesicare or placebo). The questionnaires for the evaluation of OAB syndrome, acute urinary toxicity and quality of life should be completed for each follow-up visit. The voiding diary will be completed during 3 days before (or if not, 3 days after) all the evaluation times. An urologist will perform an uroflowmetry and a post-voiding echography (or a bladder scan) before initiation of the treatment, and after 6 weeks of treatment. Statistics and sample size PATIENTS ENROLMENT 70 patients will be included (considering 66 patients completing the full study) within 3 recruitment centers
Interventions
DRUGSuccinate of Solifenacin
DRUGPlacebo of Succinate of Solifenacin
Sponsors
Center Eugene Marquis
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Prostate adenocarcinoma (histological confirmation), * Indication for prostate cancer radiotherapy (standard schema with a total dose from 70 to 80 Gray (GY)), * Patient affiliation to the French Social Security System, * Patient information and written informed consent, * Patient complaining of urinary symptoms during radiotherapy, * Occurrence of OverActive Bladder (OAB) subscore with the Urinary Symptom Profile (USP) scale greater or equal to 5.
Exclusion criteria
* Prostate irradiation contraindication * History of bladder or prostate surgery, * History of of pelvic radiotherapy, * Individual deprived of liberty or placed Under the authority of a tutor, * Age \< 18 years, * Flowmetry Qmax \< 10ml/s and/or post-void residual urine \> 100 ml (during urology preinclusion visit) * Previous known OAB * Patients treated with non-authorized drugs, * Patients treated with anticholinergic or cholinesterase inhibitors within 12 months before irradiation, * Patients treated with anticholinergic during and weeks following irradiation and before Succinate of Solifenacin treatment start, * Patients treated with botulinum toxin within 9 months before screening, * Patients treated with alpha-blockers, 5-alpha reductase inhibitor within 12 months preceding irradiation, during and weeks following irradiation and before Succinate of Solifenacin treatment start, * Contraindication of Succinate of Solifenacin * Hypersensitivity or allergy to Solifenacin succinate or to any other antimuscarinic agent, * Specific precautions of use for patients having decompensated urinary tract obstruction at risk of urinary retention, vegetative neuropathy, long QT syndrome and an hypokaliemia, history of long QT or patients at risk of QT prolongation, obstructive gastrointestinal disorders. * Patients treated with oral biphosphonates, drugs that cause QT prolongation or by substrates having affinity for CYP3A4 isoenzyme as verapamil and Diltiazem, or treated with CYP3A4 inductors as rifampicin, phenytoin, carbamazepine * Galactose hereditary intolerance, lactase deficiency or a malabsorption syndrome of glucose and galactose. * Patient enable to follow study medical care for family, social, geographical or psychological reasons. * Participation to another clinical study on urinary toxicity and/or molecule that could modify this toxicity and its evolution.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Score of Urinary Symptom Profile (USP) questionnaire | At 6 weeks | Score will be measured after study drug treatment initiation. |
Countries
France
Outcome results
None listed